Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

• Status: Completed
• Trial end date: 2017-12-12
• Target enrollment: 0
• Participant gender: All

Summary

This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have had an inadequate response to 1 anti-TNF biologic).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Methotrexate

Criteria

Inclusion Criteria

• Subjects between the ages of 18 and 75 years, inclusive

• Must have moderate-to-severe, active Rheumatoid Arthritis

• Must have had an inadequate response to Methotrexate

• Subjects may have received one approved TNF inhibiting biologic agent that was inadequately effective and/or not tolerated

Exclusion Criteria

• Subjects with any acute or chronic infections or infection history

• Have acute or active chronic dermatological disorders prior to study start

• Any major illness/condition(s) or evidence of an unstable clinical condition that in the judgment of the investigator would make the subject inappropriate for entry into this study

• Known immunodeficiency disorder or a first degree relative with hereditary immunodeficiency

• Any live (attenuated) vaccines or current routine household contact with anyone who has received live (attenuated) vaccine